Following his collaboration with other research scientists to protest the cost of cancer drugs, Hagop Kantarjian, MD, from the MD Anderson Cancer Center has now turned to patients.
Hagop M. Kantarjian, MD, Professor and Chair of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, is preparing to launch a grassroots campaign to gather patients' stories about how they are affected by high cancer drug prices.
“If we can get a million signatures online, either through Twitter or Facebook, about patients who say ‘I protest high cancer drug prices because...’ and tell their stories, this will become a major story that will put pressure on drug companies,” he said. “And it will put pressure on our elected representatives to try to reduce high cancer drug prices or to make cancer drugs affordable to all patients.”
The social media campaign is the next phase of Kantarjian's work to protest cancer drug prices, which have spiked in the past decade. As he noted in a 2013 article coauthored with Donald W. Light, PhD, 12 of the 13 new drugs approved for cancer treatment the year before were priced at more than $100,000 per year of therapy (Cancer 2013;119:3900-3902).
Complete article and interview in Oncology Times:
Late last year, Kantarjian participated in a session at the American Society of Hematology annual meeting titled “The rising cost of medical care: understanding the problem and exploring solutions.”
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
2 Commerce Drive
Cranbury, NJ 08512